Skip to main content
Premium Trial:

Request an Annual Quote

OvaGene Licenses Technologies for Potential MDx

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – OvaGene Oncology today announced it has completed licensing agreements with Norwegian researchers to validate new genomic technologies with the intention of developing them into clinical laboratory tests.

The Irvine, Calif.-based based firm has licensed a proprietary method from the University of Bergen Tech Office BTO for identifying high-risk endometrial cancer patients diagnosed with early-stage cancer. The technology can identify a molecular component in early-stage patients linked with high risk, OvaGene said in a statement.

It has also licensed a proprietary method from Medinnova for determining chemoradiation resistance in cervical cancer. Further studies are planned to validate the technology, which may allow patients to be tested for chemoradiation resistance before therapy is started.

Details about the agreements were not disclosed.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.